Home » Topics » BioWorld Science

BioWorld Science
RSS

When a bear spits in the woods

Sep. 10, 2018

Optimized 1,4-oxazine BACE1 inhibitor shows improved safety profile in preclinical studies

Sep. 10, 2018

Compugen initiates clinical testing of COM-701 in advanced solid tumors

Sep. 7, 2018

Checkpoint Therapeutics reports promising phase I/II data with CK-101 in EGFR-mutated NSCLC

Sep. 7, 2018

Soleno amends phase III trial protocol for diazoxide choline in Prader-Willi syndrome

Sep. 7, 2018

NIH grants supports Hepseros' development of human-on-a-chip technology

Sep. 7, 2018

Atara Biotherapeutics to develop CAR T immunotherapies with Moffitt Cancer Center

Sep. 7, 2018

Luye initiates phase III trials in China with LY-01005 for prostate cancer

Sep. 7, 2018

Eli Lilly presents AOC3 inhibitors

Sep. 7, 2018

Phase IIa study of Yeliva for cholangiocarcinoma advances to second stage

Sep. 7, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 17, 2026.
Celia trial: data strong, analysts skeptical
BioWorld
Tuesday brought what was arguably the most anticipated presentation of the 2026 Alzheimer’s Association International Conference when Catherine Mummery, head of...
Dual FAAH/MAGL inhibition targets Alzheimer’s disease hyperexcitability
BioWorld Science
Reduced endocannabinoid signaling has been linked to neuronal hyperexcitability in Alzheimer’s disease (AD), suggesting that dual inhibition of fatty acid amide...
ALN-5288 lowers tau levels in preclinical models
BioWorld Science
Pathological tau accumulation is a key driver of neurodegeneration in Alzheimer’s disease (AD) and other tauopathies such as progressive supranuclear palsy....
Capital remains selective in ‘barbell’ biotech market
BioWorld
Signs of recovery are emerging in the biotechnology investment sector, although investors across Asia say that capital is flowing selectively to companies that...